ACE and diabetes mellitus: Four of the patients were receiving blood pressure reducing therapy (2 with diabetes of which one patient was receiving β-Blocker therapy alone and one receiving both a calcium channel blocking agent with an angiotensin II receptor antagonist and 2 without diabetes: one receiving a combination of β-blocker and an angiotensin-converting enzyme inhibitor therapies and the other receiving a calcium channel blocking agent along with an angiotensin-converting enzyme Inhibitor).